RxDoctor Payments Data

Benjamin Brannick

Podiatrist · Hoover, ALNPI 1932693140

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Amgen at 29.5% of the total.

$2,534in general payments, 2019–2025

Across 69 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$748
  • Stryker$539
  • Paratek Pharmaceuticals, Inc.$316
  • Averitas Pharma Inc.$273
  • Kerecis Limited$246
  • Organogenesis Inc.$221
  • plus $192 from 6 others

What the payments were for

  • Food & beverage$2,534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,534 in reported general payments places this provider in the 75th percentile of 59 podiatrist providers in Alabama.

See all podiatrist providers in Alabama

Medicare billing

Part B allowed, 2024
$132,639
Medicare patients
736
Services billed
2,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole199$5,719
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip32$1,987
Ketoconazole83$1,753
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav49$832
Triamcinolone Acetonide90$766
Diclofenac Sodium21$702
Ammonium Lactate26$679
Terbinafine Hcl24$492
Ciclopirox12$364
SsdSilver Sulfadiazine20$288
Cephalexin29$270
Colchicine13$118
Doxycycline Hyclate15$89
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$80
Silver Sulfadiazine12$66

Paid to pharmacies, not to this prescriber.

Other podiatrist in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →